Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov 27;69(12):2059-2070.
doi: 10.1093/cid/ciz133.

Impact of Rotavirus Vaccine Introduction in Children Less Than 2 Years of Age Presenting for Medical Care With Diarrhea in Rural Matlab, Bangladesh

Lauren M Schwartz  1   2 , K Zaman  3 , Md Yunus  3 , Ahasan-Ul H Basunia  3 , Abu Syed Golam Faruque  3 , Tahmeed Ahmed  3 , Mustafizur Rahman  3 , Jonathan D Sugimoto  2 , M Elizabeth Halloran  1   2   4   5 , Ali Rowhani-Rahbar  1 , Kathleen M Neuzil  6 , John C Victor  7
Affiliations

Impact of Rotavirus Vaccine Introduction in Children Less Than 2 Years of Age Presenting for Medical Care With Diarrhea in Rural Matlab, Bangladesh

Lauren M Schwartz et al. Clin Infect Dis. .

Abstract

Background: Following the conclusion of a human rotavirus vaccine (HRV) cluster-randomized, controlled trial (CRT) in Matlab, Bangladesh, HRV was included in Matlab's routine immunization program. We describe the population-level impact of programmatic rotavirus vaccination in Bangladesh in children <2 years of age.

Methods: Interrupted time series were used to estimate the impact of HRV introduction. We used diarrheal surveillance collected between 2000 and 2014 within the 2 service delivery areas (International Centre for Diarrhoeal Disease Research, Bangladesh [icddr,b] service area [ISA] and government service area [GSA]) of the Matlab Health and Demographic Surveillance System, administered by icddr,b. Age group-specific incidence rates were calculated for both rotavirus-positive (RV+) and rotavirus-negative (RV-) diarrhea diagnoses of any severity presenting to the hospital. We used 2 models to assess the impact within each service area: Model 1 used the pre-vaccine time period in all villages (HRV- and control-only) and Model 2 combined the pre-vaccine time period and the CRT time period, using outcomes from control-only villages.

Results: Both models demonstrated a downward trend in RV+ diarrheal incidences in the ISA villages during 3.5 years of routine HRV use, though only Model 2 was statistically significant. Significant impacts of HRV on RV+ diarrhea incidences in GSA villages were not observed in either model. Differences in population-level impacts between the 2 delivery areas may be due to the varied rotavirus vaccine coverage and presentation rates to the hospital.

Conclusions: This study provides initial evidence of the population-level impact of rotavirus vaccines in children <2 years of age in Matlab, Bangladesh. Further studies are needed of the rotavirus vaccine impact after the nationwide introduction in Bangladesh.

Keywords: impact; rotavirus vaccine; time-series.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Observed counts of rotavirus-positive (RV+) and rotavirus-negative (RV–) diarrhea of any severity, presenting to Matlab Hospital in (A) ISA and (B) GSA areas. Abbreviations: CRT, cluster-randomized controlled trial; GSA, government service area; ISA, International Centre for Diarrhoeal Disease Research, Bangladesh, service area; RCT, randomized, controlled trial; YR, year.
Figure 2.
Figure 2.
Timing of HRV coverage (dose 1) over time by ISA and GSA villages randomized to HRV or control only in <1-year-olds. Abbreviations: GSA, government service area; HRV, human rotavirus vaccine; ISA, International Centre for Diarrhoeal Disease Research, Bangladesh, service area. ISA, HRV: icddr, b service areas randomized to HRV during the CRT; ISA, Control: icddr, b service areas randomized as control-only villages during the CRT; GSA, HRV: Government service areas randomized to HRV during the CRT; GSA, Control: icddr, b service areas randomized as control-only villages during the CRT; *23 children were vaccinated in GSA Villages in September-October 2008 before the start of the cluster-randomized trial (CRT). This time period is still considered prevaccine due to the small number of children vaccinated.
Figure 3.
Figure 3.
Observed incidences and IRRs of RV+ and RV– diarrhea of any severity presenting to Matlab Hospital in ISA villages using Models 1 and 2 in (A) 0– to <12-month-old children and (B) 12 to <24-month-old children. Abbreviations: CI, confidence interval; CRT, cluster-randomized controlled trial; IRR, incidence rate ratio; ISA, International Centre for Diarrhoeal Disease Research, Bangladesh, service area; RV–, rotavirus negative; RV+, rotavirus positive; RCT, randomized, controlled trial; YR, year.
Figure 4.
Figure 4.
Observed incidence and IRRs of RV+ and RV– diarrhea of any severity presenting to Matlab Hospital in GSA villages using Models 1 and 2 in (A) 0 to <12-month-old children and (B) 12 to <24-month-old children. Abbreviations: CI, confidence interval; CRT, cluster-randomized controlled trial; GSA, government service area; IRR, incidence rate ratio; RV–, rotavirus negative; RV+, rotavirus positive; RCT, randomized, controlled trial; YR, year.
See this image and copyright information in PMC

Comment in

References

    1. Troeger C, Khalil IA, Rao PC, et al. Rotavirus vaccination and the global burden of rotavirus diarrhea among children younger than 5 years. JAMA Pediatr 2018;172:958–65. - PMC - PubMed
    1. Troeger C, Forouzanfar M, Rao PC, et al. Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the global burden of disease study 2015. Lancet Infect Dis 2017; 17:909–48. - PMC - PubMed
    1. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010; 362:289–98. - PubMed
    1. Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376:606–14. - PubMed
    1. International Vaccine Access Center Johns Hopkins Bloomberg School of Public Health. VIEW-hub global vaccine introduction and implementation report. Available at: www.jhsph.edu/ivac/view-hub. Accessed 23 March 2018.

Publication types

Substances